The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00 ...

Fintel reports that on April 25, 2025, Wells Fargo downgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

Wall Street expects a year-over-year increase in earnings on higher revenues when United Therapeutics (UTHR) reports results for the quarter ended March 2025. While this widely-known consensus outlook ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from Underperform to Neutral. As of April 2, 2025, the average one-year ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 16, 2025--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results ...